Inflammatory bowel disease rates on the rise outside West, says new study

08 Dec 2017 --- Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialized and Westernized, a new study has found. The research – a collaboration between the University of Birmingham, UK, the University of Calgary, Canada, and the Chinese University of Hong Kong – is described by the University of Birmingham as the most definitive and comprehensive study of the global epidemiology of inflammatory bowel disease.

Future research should now focus on identifying environmental risk factors observed during the early stages of industrialization of society in order to highlight avenues to prevent the development of the disease, the University of Birmingham observes. The data also highlights the need for research into prevention of inflammatory bowel disease and innovations in health-care systems to manage the complex and costly disease.

Accelerating incidence outside West
The study, published in The Lancet, is a systematic review of 147 world-wide observational studies reporting on the incidence or prevalence of two of the main conditions of inflammatory bowel disease – Crohn’s disease and ulcerative colitis – between 1990 and 2016.

“Our study shows that, at the turn of the 21st century, inflammatory bowel disease has become a global disease with accelerating incidence in newly industrialized countries whose societies have become more Westernized,” says Professor Subrata Ghosh, Director of the Institute of Translational Medicine.

“We have shown an accelerating incidence in countries in Africa, Asia, the Middle East and South America that mirrors inflammatory bowel disease incidence in the Western world during the latter half of the 20th century,” Professor Ghosh continues.

“While our study demonstrates a paradigm shift whereby the incidence of inflammatory bowel disease in most Western countries has begun to stabilize and in some regions decrease, it is important to note that the prevalence of the disease is now 0.3 percent of the population in North America, Australia and most countries in Europe,” Dr. Gilaad Kaplan, of the University of Calgary in Canada, says.

“The high prevalence of this disease in the Western world will challenge clinicians and health policy makers to provide quality and cost-efficient care to patients with this condition,” Dr. Kaplan adds.

Professor Siew Ng, of The Chinese University of Hong Kong, notes: “The rapid increase in incidence in many countries, especially in children, within one to two decades suggests strong environmental influence within a genetically susceptible population.”

“The peak in the incidence of this disease has likely not transpired in newly industrialized countries. Consequently, these countries will need to prepare their clinical infrastructure and personnel to manage what is a complex and costly disease to treat,” adds Professor Ng.